Monitor for trial initiation updates, regulatory interactions, and future financing needs — this early-stage program may require significant capital before generating data.
Price Chart
Executive Summary
Liminatus Pharma announced plans to initiate a Phase 1 clinical trial for IBA101, a next-generation CD47-blocking antibody, in lung cancer, initially as monotherapy and later in combination with PD-1/PD-L1 inhibitors. The trial is still in preclinical planning stages, with no dosing or patient data yet available.
Key Facts
- Liminatus Pharma plans a Phase 1 trial for IBA101, a CD47-blocking monoclonal antibody.
- Trial will begin with monotherapy dose escalation, followed by combination cohorts with PD-1/PD-L1 inhibitors.
- Lung cancer is the initial focus, leveraging existing PD-1/PD-L1 treatment paradigms.
- No clinical data exists yet; trial has not started and remains contingent on manufacturing, regulatory, and nonclinical preparations.
- Dr. Se-Hoon Lee will lead the clinical program; translational analyses will be included.
Financial Impact
No immediate financial impact; potential long-term value if clinical milestones are achieved
Risk Factors
- High risk of failure inherent in early-stage biotech development
- No guarantee of regulatory green light or successful manufacturing scale-up
- Potential for future dilutive financings to fund trial execution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257130 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 18, 2026 10w ago | 8-K | $0.1117 $0.0678 | ▲ +39.30% | ▲ +38.46% | $2.88 (−2478.33%) |
Jul 6, 2026 16w ago | 8-K | $0.1426 $0.1137 | ▲ +20.27% | ▲ +21.12% | $2.88 (−1919.64%) |
Jun 23, 2026 17w ago | S-1 | $0.1031 $0.1187 | ▲ +15.13% | ▲ +14.46% | $2.88 (+2693.40%) |
May 21, 2026 22w ago | Press Release | $0.1690 $0.1089 | ▲ +35.56% | ▲ +34.15% | $2.88 (−1604.14%) |
Mar 17, 2026 32w ago | Press Release | $0.2300 $0.1860 | ▼ −19.13% | ▼ −23.43% | $2.88 (+1152.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers